Trevi Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

TRVI$14.91-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(Amounts in thousands)

	Three Months Ended March 31,
	2025	2024
Operating activities:
Net loss	$(10,340)	$(10,902)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,208	723
Operating lease right-of-use assets	112	120
Depreciation and amortization	37	35
Accretion of available-for-sale marketable securities, net	(395)	(381)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(605)	584
Accrued expenses and other liabilities	(1,501)	(940)
Accounts payable	(1,993)	294
Net cash used in operating activities	(13,477)	(10,467)
Investing activities:
Proceeds from maturities of available-for-sale marketable securities	17,595	22,173
Purchases of available-for-sale marketable securities	(27,546)	(30,264)
Net cash used in investing activities	(9,951)	(8,091)
Financing activities:
Proceeds from exercises of warrants	8,220	—
Proceeds from exercises of stock options	718	4
Payments of offering costs	(222)	—
Payments of finance lease	(11)	(32)
Net cash provided by (used in) financing activities	8,705	(28)
Net decrease in cash and cash equivalents	(14,723)	(18,586)
Cash and cash equivalents at beginning of period	34,097	32,397
Cash and cash equivalents at end of period	$19,374	$13,811

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.